Sun Pharmaceutical Industries Ltd (SMPQY) CEO Abhay Gandhi on Q1 2021 Results - Earnings Call Transcript

published 01.08.2020 10:05

Image of article 'Sun Pharmaceutical Industries Ltd (SMPQY) CEO Abhay Gandhi on Q1 2021 Results     -     Earnings Call Transcript'

Although we recorded a 33% decline year-on-year, the numbers are not strictly comparable as sales for Q1 last year included a onetime contribution from the specialty business in U.S. Let me now update you on developments in our specialty business.

For Q1, sales of branded formulation in India were INR2,388 crores, a growth of 3.2% over Q1 last year, accounting for approximately 32% of total sales.

Other expenditure was at 28% of sales, lower than Q1 last year mainly due to reduced marketing, selling and traveling expenses across markets.

Staff cost was at 23.6% of sales, higher than Q1 last year all due to a lower sales base, an increase in field staff in India and the U.S.

Material cost as a percentage of sales was 26.4%, lower than Q1 last year due to product mix.

by My Authors from seekingalpha.com

Free awesomeness straight to your inbox!

Sign up now for this free newsletter to receive hand picked content, covering topics like Lifestyle, Business & Technology.

Free Newsletter Sign up now!

..or jump directly to the latest posts!